Welcome to our dedicated page for NewcelX SEC filings (Ticker: NCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NewcelX Ltd. (Nasdaq: NCEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. NewcelX reports under the Exchange Act on Form 20-F and furnishes current reports on Form 6-K, offering investors structured insight into its operations as a Swiss clinical-stage biopharmaceutical and biotechnology company focused on neurodegenerative and metabolic diseases.
Through these filings, readers can follow key corporate events connected to the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., which established NewcelX as a combined entity integrating cell-therapy platforms with neuroscience and small-molecule expertise. For example, a Form 6-K details the post-merger appointment of Kost Forrer Gabbay & Kasierer, a member of Ernst & Young, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and describes the prior engagement and dismissal of CBIZ CPAs, P.C., along with references to previously disclosed material weaknesses.
On Stock Titan, NewcelX filings such as annual reports on Form 20-F, interim and event-driven Form 6-K submissions, and related exhibits can be viewed alongside AI-powered summaries. These summaries are designed to highlight essential elements of lengthy documents, helping users quickly identify information on topics like accounting firm changes, internal control disclosures, merger-related details, and other governance matters discussed in the filings.
Investors researching NCEL can use this page to monitor how NewcelX describes its business, risk factors, financial reporting framework, and post-merger integration steps over time. Real-time updates from EDGAR combined with AI-assisted overviews aim to make complex regulatory content more accessible without replacing the need to review the full original filings.
NewcelX Ltd. reported a 2025 net loss of $8.3 million, driven largely by $5.7 million of non-cash finance expenses linked to convertible instruments that were converted before completion of its merger. Operating loss was $2.6 million, reflecting research and development and general and administrative spending typical for a clinical-stage company.
Cash and cash equivalents were $2.2 million as of December 31, 2025, and the balance sheet shows total assets of $11.4 million and equity of $7.3 million, with the company describing itself as substantially debt free. In April 2026, NewcelX completed a $1.35 million private placement with up to approximately $2.0 million of additional potential warrant proceeds and retains access to a $25 million equity line of credit. The company is prioritizing development of its NCEL-101 stem-cell-derived therapy for Type 1 Diabetes in collaboration with Eledon Pharmaceuticals and continues to advance its broader cell therapy pipeline, including AstroRx for ALS and DOXA for narcolepsy and other CNS indications.
NewcelX Ltd. files its annual Form 20-F as a clinical-stage pharmaceutical company developing allogeneic, “off-the-shelf” cell therapies based on hESC technology. The report highlights NewcelX’s October 2025 merger with Kadimastem and a 1-for-10 reverse share split with CHF 0.05 par value.
Holders of Kadimastem ordinary shares received 0.706 NewcelX common shares per share in the merger. NewcelX reports net losses of approximately $8.3 million in 2025 and $7.2 million in 2024, with an accumulated deficit of about $84.9 million as of December 31, 2025 and total equity of roughly $7.25 million.
The company has 4,797,505 common shares outstanding as of December 31, 2025 and 5,345,184 common shares as of April 29, 2026. NewcelX has no product revenue, depends on external financing, and discloses substantial doubt about its ability to continue as a going concern while advancing AstroRx for neurodegenerative diseases and NCEL-101 for insulin-dependent diabetes.
NewcelX Ltd. director Samuel Olivier reported open-market purchases of both common shares and warrants. He bought 81,818 common shares of NewcelX at $2.75 per share, with each share sold together with a warrant according to the footnote.
Olivier also acquired 114,545 warrants, each exercisable at $3.025 per common share and expiring on April 27, 2031. Following these transactions, he directly holds 81,818 common shares and 114,545 warrants, reflecting a net addition of 196,363 share-equivalents to his position.
NewcelX Ltd. CSO and Director Revel Michel reported open-market purchases of common shares and warrants. He bought 54,545 common shares at $2.75 per share and acquired 76,363 warrants, each giving the right to buy one common share at $3.025.
The filing states the combined purchase price for one common share and one accompanying warrant was $2.75. Following these transactions, Michel directly holds 957,530 common shares, alongside 76,363 warrants expiring on April 27, 2031.
NewcelX Ltd. furnished a Form 6-K featuring an updated corporate and investor presentation that elevates its Type 1 Diabetes flagship program, NCEL-101, as the core value driver. The program uses enriched stem-cell-derived islets as scalable cell replacement therapy.
The materials describe integrating NewcelX’s islet replacement platform with Eledon Pharmaceuticals’ investigational anti-CD40L antibody tegoprubart to support durable graft survival and pursue a potential functional cure for Type 1 Diabetes. The presentation also outlines a broader pipeline in diabetes and CNS disorders, including AstroRx for ALS and the DOXA orexin agonist platform.
NewcelX Ltd. announced a private placement financing with accredited investors, selling 490,907 common shares (or pre-funded warrants) at $2.75 per share, a 30% premium to the prior closing price, and issuing common warrants to purchase up to 687,270 shares at an exercise price of $3.025 per share.
The transaction is expected to provide gross proceeds of $1.35 million, with an additional approximately $2.1 million possible from full cash exercise of the warrants. NewcelX plans to use the proceeds, alongside its previously announced $25 million equity line, to advance NCEL-101, its lead stem-cell-based therapy program for Type 1 Diabetes, as well as other pipeline programs, working capital and general corporate purposes.
The offering is expected to close on or about April 15, 2026, subject to customary closing conditions, and the securities are being issued under Section 4(a)(2) and Rule 506(b) of Regulation D, with a commitment to file a resale registration statement for the underlying shares.
NewcelX Ltd. director Galili Tamar filed an initial ownership report showing an option to purchase 9,117 ordinary shares. The option has an exercise price of $7.6200 per share and expires on November 4, 2035. As of this filing, options to purchase 759 ordinary shares are vested and currently exercisable, while the remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to continued service. The options were granted under the NewcelX Ltd. Share Option Plan Regulation 2021 and, to qualify for certain Israeli tax benefits, must be registered in the name of a trustee.
NewcelX Ltd. director, Chairman and CEO Ronen Twito has filed an initial Form 3 showing beneficial ownership of 272,399 Ordinary Shares of the company. According to the disclosure, these shares are held by Altshare Trust Ltd on his behalf under Section 102 of the Israeli Tax Ordinance. The filing records his starting equity position as an insider, without reporting any specific recent share purchases or sales.
NewcelX Ltd. CSO and director Revel Michel filed an initial ownership report. He directly holds 940,787 ordinary shares and options on 9,117 ordinary shares at an exercise price of $7.6200 expiring on November 4, 2035. As of this filing, 759 option shares are vested and exercisable, with the remainder vesting in 11 equal quarterly installments beginning May 4, 2026, subject to his continued service. Certain option grants are held through a trustee to qualify for Israeli tax benefits under Section 102 of the Israeli Tax Ordinance.
NewcelX Ltd. filed an initial insider ownership report for Chief Financial Officer Hagai Omri, disclosing an option to purchase 11,396 ordinary shares. The option has an exercise price of $7.6200 per share and expires on November 4, 2035.
As of the filing date, options to purchase 949 ordinary shares are vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to Omri’s continued service with the company.